共 30 条
[1]
Slamon DJ(2001)Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783-792
[2]
Leyland-Jones B(2005)Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673-1684
[3]
Shak S(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672
[4]
Romond EH(2006)Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2733-2743
[5]
Perez EA(2007)Trastuzumab treatment beyond progression in patients with HER2-positive metastatic breast cancer the TBP study (GBG 26/BIG 3–05) Breast Cancer Res Treat 106 S185-5417
[6]
Bryant J(2007)Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: results from the Hermine cohort study Eur J Cancer Suppl 5 213-undefined
[7]
Piccart-Gebhart MJ(2007)Lapatinib plus capecitabine in HER2-positive advanced breast cancer: Genomic and updated efficacy data J Clin Oncol ASCO Annual Meeting Proceedings, Part I 25 1035-undefined
[8]
Procter M(2007)Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 5410-undefined
[9]
Leyland-Jones B(2007)HKI-272, an irreversible pan erbB receptor tyrosine kinase inhibitor: preliminary phase 2 results in patients with advanced breast cancer Breast Cancer Res Treat 106 S268-undefined
[10]
Geyer CE(2007)A phase I study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with advanced HER2-positive breast cancer Breast Cancer Res Treat 106 S33-undefined